Ubisoft is apparently endeavoring to work with Tencent to bring forth new ventures, one of which is the rumored Splinter Cell Remake. During an address, Guillemot confirmed numerous titles were in ...

The Allen Brain Cell Atlas (ABC Atlas) aims to empower researchers worldwide to explore and analyze multiple whole-brain datasets simultaneously. As the Allen Institute and its collaborators continue ...

Swiss IoT module maker u-blox is to phase out its loss-making cellular IoT business, the firm has said. The division has over 200 employees; jobs are expected to go with its closure. It made revenue ...

The network is called Lunar Surface Communication System (LSCS), and it is basically a replica of the 4G/LTE cellular technology currently used on a very large scale by the humans of Earth.

(Reuters) - Johnson & Johnson said on Monday it would buy neurological drug maker Intra-Cellular Therapies for $14.6 billion, its biggest deal in more than two years, boosting its presence in the ...

“This scale-up collaboration is another powerful example of how we are driving innovation in food production,” says chair of the Cellular Agriculture Netherlands Foundation, Maresa Oosterman. “By ...

UPDATE 2/9: T-Mobile has since expanded its beta to iPhones running iOS 18.3. And it just revealed in a Super Bowl ad that its cellular Starlink service will launch in July. It'll be free for ...

In a dark coincidence, the researchers point to California's current catastrophe as a timely example of their recently published findings. "In that publication, fairly incredibly, we use the example ...

8, 2024. (AP Photo/Ted Shaffrey, File) Updated [hour]:[minute] [AMPM] [timezone], [monthFull] [day], [year] Johnson & Johnson will spend more than $14 billion to delve further into the treatment of ...

Mario Tama / Getty Images Shares of Intra-Cellular Therapies jumped Monday morning after Johnson & Johnson announced plans to buy the biopharmaceutical company. Intra-Cellular shareholders will ...

Johnson & Johnson has opened the J.P. Morgan Healthcare Conference with a bang, buying out Intra-Cellular Therapies for $14.6 billion. At $132 per share, J&J paid a 39% premium on Friday’s ...